Peak Wall Stress as a prognostic indicator of abdominal Aortic Aneurysm rupture risk (Old ID 26250)
Role
Chief Investigator
Description
Abdominal Aortic Aneurysm (AAA) affects 20 million people worldwide and 100,000 people in Australia. Annually, AAA rupture leads to 200,000 deaths worldwide and 2000 deaths in Australia. In clinical practice, maximum AAA diameter is the preferred surrogate measure for disease progression and rupture risk, and is used to guide surgical intervention. Approximately 10% of AAAs will rupture before they reach the current threshold for repair, whereas 60% of large AAAs remain stable during their lifetime, suggesting that diameter alone is an imperfect tool to decide which AAAs require surgical intervention. The specific aims of the project are Aim 1: To investigate if PWS is greater in patients with ruptured compared to intact AAAs matched for diameter; Aim 2: To evaluate the impact of a common anti-hypertensive medication {Telmisartan) on PWS and rupture risk in patients with small AAAs.
Date
01 Jul 2018 - 31 Dec 2020
Project Type
GRANT
Keywords
Metformin;Abdominal Aortic Aneurysm;Ruptures
Funding Body
Townsville Hospital and Health Service
Amount
50000
Project Team
Joseph Moxon;Jonathan Golledge